Skyrizi (risankizumab-rzaa) is an AbbVie biologic approved for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease and ulcerative colitis. For skin and joint disease, FDA labeling puts adults on 150 mg at week 0, week 4, and every 12 weeks after that, which means four maintenance doses a year rather than a monthly refill.
That dosing schedule is the key to reading any Skyrizi price. Almost every number you will see quoted, including AbbVie’s own, is a per-dose figure in the five figures, and it only makes sense once you divide it across three months. Every figure below was verified on September 1 and 2, 2026. This page is about cost and paperwork only, not about whether the drug is right for you.
What Does Skyrizi Cost Without Insurance?
AbbVie publishes Skyrizi’s list price on the drug’s own cost pages, stated as of January 6, 2026, with the surrounding cost table described as accurate as of January 14, 2026. Retail cash figures come from SingleCare’s live pages, prices updated September 2, 2026. The Medicare row comes from CMS’s Medicare Part D Spending by Drug dataset, data year 2024, released June 25, 2026.
| Option | Low | Average / typical | High |
|---|---|---|---|
| Skyrizi 150 mg pen, average retail cash | $21,938.37 | $21,938.37 | $21,938.37 |
| Skyrizi 150 mg pen, cash with a discount card | $21,935.37 | $21,935.37 | $21,935.37 |
| AbbVie published list price, one dose | $23,838.42 | $23,838.42 | $23,838.42 |
| Medicare Part D average per pen fill, 2024 | $20,782.08 | $20,782.08 | $20,782.08 |
| Skyrizi 600 mg IV vial, cash (induction dose) | $10,360.32 | $14,915.87 | $14,915.87 |
| Skyrizi Complete Savings Card (commercial insurance only) | $0 | $0 | $0 |
| Medicaid | $8.00 or less per month | $8.00 or less per month | $8.00 or less per month |
| myAbbVie Assist (income-qualified) | $0 | $0 | $0 |
The cross-source range for one uncovered 150 mg dose is roughly $21,938 to $23,838. Spread across the every-12-week schedule, that is about $7,313 to $7,946 a month, or somewhere between $87,753 and $95,354 a year in maintenance alone. First-year cost is higher, because the label adds a starting dose at week 4.
One caution on the discount-card row: SingleCare’s per-pharmacy figures shift between sessions, so treat any named-chain quote as illustrative rather than fixed. The average retail and as-low-as figures are the ones that hold steady.
The discount card does almost nothing here
This is worth saying plainly because it is the opposite of what people expect. On the 150 mg pen, SingleCare’s average retail price is $21,938.37 and its card price is $21,935.37. That is a $3 difference, which is the value of the signup bonus, not a negotiated discount.
Discount cards are built around retail generics with real competition behind them. Skyrizi is dispensed through specialty pharmacies at a price set almost entirely by the manufacturer, so there is nothing for a card to squeeze. The exception is the 600 mg per 10 mL intravenous vial used for Crohn’s and ulcerative colitis induction, where SingleCare shows an as-low-as price of $10,360.32 against a $14,915.87 average retail figure.
What Medicare’s own data shows
CMS Part D data is a useful reality check because it reports what was actually paid nationally. In 2024, Part D covered 85,713 Skyrizi pen fills for 27,003 beneficiaries at an average of $20,782.08 per fill and $1.78 billion in total spending. Average spending per beneficiary was $65,966.53 for the year. The on-body injector version averaged $20,316.26 per fill and $79,759.04 per beneficiary.
What Drives the Price
There is no biosimilar. FDA’s biosimilar product list, content current as of August 4, 2026, contains no risankizumab product. Without a cheaper equivalent, the price is whatever AbbVie sets, which is why the manufacturer programs carry all the weight on this page.
Which condition you are treating. Psoriasis and psoriatic arthritis run on 150 mg every 12 weeks. Crohn’s disease and ulcerative colitis start with intravenous induction at weeks 0, 4 and 8, then move to a 180 mg or 360 mg subcutaneous maintenance dose at week 12 and every 8 weeks after that. The gastrointestinal path involves more doses per year and infusion charges on top of the drug.
Which device your prescription specifies. Skyrizi comes as a 150 mg prefilled pen or syringe, a 55 mg syringe, a 600 mg vial for infusion, and 180 mg or 360 mg cartridges with an on-body injector. CMS data shows meaningfully different average costs per fill across those forms, so confirm the exact presentation before you price it.
Your insurance status, in both directions. The $0 savings card requires commercial coverage. The free-drug program requires limited or no coverage. A patient with a thin commercial plan that excludes Skyrizi can fall between the two, which is the worst place to be.
Whether your plan runs an alternate funding program. AbbVie states that patients whose commercial plan requires them to apply to myAbbVie Assist as a condition of coverage are not eligible for myAbbVie Assist. That is an explicit block on a practice some employer plans use to push specialty drug costs onto charity programs.
Cash Price vs. Insurance
For an uninsured patient there is no version of this where paying cash is the plan. Twenty-two thousand dollars a dose, four times a year, is not a bill anyone absorbs, and unlike a generic there is no cheaper equivalent to fall back on. The realistic path is myAbbVie Assist, which AbbVie says provides free AbbVie medicines to patients with limited or no insurance who meet its published income criteria: $63,840 or less for a household of one, $86,560 for two, $109,280 for three and $132,000 for four, plus $22,720 for each additional dependent.
If you have commercial insurance, run the claim and use the Skyrizi Complete Savings Card, which AbbVie advertises at $0 per dose four times a year for eligible patients. Monthly maximums may apply and the offer excludes anyone with Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, DoD or VA coverage.
Medicare and Medicaid enrollees land in a different place. AbbVie’s own table puts Medicaid at $8.00 or less per month depending on state plan, and Medicare Part D at $0 to $2,100 per dose depending on coverage phase, with the 2026 Part D annual out-of-pocket cap set at $2,100 for all covered drugs. Patients with the Medicare Low Income Subsidy pay $12.65 or less per dose starting January 1, 2026. Part D enrollees can also spread that cap across the year through the Medicare Prescription Payment Plan.
If a pharmacy or a plan quotes you a figure that matches nothing here, our fair price checker is a fast way to see whether it is defensible.
How to Pay Less
-
Apply to myAbbVie Assist before anything else if you are uninsured. It is free to apply, approved patients receive the medicine at no cost, and the published income ceilings are far higher than most people assume: $132,000 for a household of four.
-
Use the Skyrizi Complete Savings Card if you are commercially insured. AbbVie advertises $0 per quarterly dose, plus $0 for each of the two starting doses at week 0 and week 4. Read the monthly maximum language before you assume the whole year is covered.
-
Do not spend time on a discount card for the pen. The card is worth $3 on the 150 mg pen. Save the effort for the assistance application. Our comparison of GoodRx vs. SingleCare explains where those cards do and do not move the needle.
-
Do not count on a copay foundation if you are uninsured. The HealthWell Foundation states that you must have some form of health insurance that covers part of your treatment, that drug discount cards do not qualify as insurance, and that it refers patients without prescription insurance to manufacturer programs instead. Most copay charities work the same way.
-
Get the visits and lab work priced separately. A free or sliding-scale clinic can handle the prescribing visits and the screening and monitoring labs that come with starting a biologic, and our guide to blood work costs without insurance covers what those panels run on cash.
-
Handle infusion and facility bills separately. For the Crohn’s and ulcerative colitis induction doses, the infusion site bills on its own. Our medical bill negotiation guide covers what to say before paying, and hospital charity care can erase the facility side outright if you qualify.
Bottom Line
Budget $21,938 to $23,838 per 150 mg dose of Skyrizi if you are paying cash in September 2026, which is roughly $7,300 to $7,950 a month once you spread it across the every-12-week schedule, or about $87,750 to $95,350 a year in maintenance. Medicare Part D averaged $20,782.08 per pen fill in 2024, so the manufacturer’s list price is not far off what a large payer actually pays.
None of that is the number to plan around. With no biosimilar in sight and discount cards worth $3, the entire game is which program you qualify for: the savings card if you are commercially insured, myAbbVie Assist if you have little or no coverage. For the other biologics priced this way, see Tremfya and Dupixent, and for the oral alternatives in the same treatment conversation, Rinvoq and Otezla. Humira shows what happens to a drug like this once biosimilars finally arrive.